Point72 Asset Management L.P. Increases Stake in ADMA Biologics, Inc. (NASDAQ:ADMA)

Point72 Asset Management L.P. lifted its stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 7.3% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 111,011 shares of the biotechnology company’s stock after purchasing an additional 7,556 shares during the period. Point72 Asset Management L.P.’s holdings in ADMA Biologics were worth $2,219,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ADMA. Bank of Montreal Can acquired a new stake in ADMA Biologics during the second quarter worth about $17,886,000. D. E. Shaw & Co. Inc. grew its stake in shares of ADMA Biologics by 26.8% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 6,824,517 shares of the biotechnology company’s stock valued at $76,298,000 after buying an additional 1,442,799 shares during the period. Principal Financial Group Inc. grew its stake in shares of ADMA Biologics by 785.7% in the 3rd quarter. Principal Financial Group Inc. now owns 1,194,221 shares of the biotechnology company’s stock valued at $23,872,000 after buying an additional 1,059,394 shares during the period. First Turn Management LLC acquired a new stake in shares of ADMA Biologics during the 3rd quarter worth approximately $13,293,000. Finally, Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in shares of ADMA Biologics during the 2nd quarter valued at approximately $6,468,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

Insider Transactions at ADMA Biologics

In other ADMA Biologics news, CFO Brad L. Tade sold 15,000 shares of the stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $21.15, for a total transaction of $317,250.00. Following the sale, the chief financial officer now directly owns 199,433 shares in the company, valued at $4,218,007.95. This represents a 7.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 3.70% of the company’s stock.

ADMA Biologics Stock Down 4.1 %

Shares of NASDAQ ADMA opened at $19.01 on Tuesday. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. The business’s 50 day moving average is $19.08 and its two-hundred day moving average is $15.83. ADMA Biologics, Inc. has a 52-week low of $3.60 and a 52-week high of $23.64. The firm has a market cap of $4.49 billion, a price-to-earnings ratio of 67.89 and a beta of 0.70.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.13 by $0.02. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The firm had revenue of $119.84 million for the quarter, compared to the consensus estimate of $107.25 million. During the same quarter in the previous year, the business earned $0.01 EPS. Research analysts predict that ADMA Biologics, Inc. will post 0.52 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the company. Raymond James increased their price objective on ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research report on Friday, November 8th. Cantor Fitzgerald reiterated an “overweight” rating and set a $20.00 price target on shares of ADMA Biologics in a report on Friday, September 20th. Finally, HC Wainwright raised their price objective on ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, November 8th.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.